Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Dr. Gonzalo Hidalgo, a Neurologist at Reliant Specialty Infusions, said he believes his clinic is the first in Louisiana to ...

The Committee for Medicinal Products for Human Use recommended against approving Eli Lilly’s Kisunla because it considered the risks of a type of brain swelling known as amyloid-related imaging ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect ...

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

But to me, one of the biggest hidden opportunities inside Lilly's ecosystem is Kisunla. Kisunla was approved by the Food and Drug Administration (FDA) last summer and represents Lilly's entrance ...

The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee for ...

The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. Advertisement Article ...